Shares of SenesTech Inc (NASDAQ:SNES) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokerages have set a one year consensus target price of $9.38 for the company and are predicting that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also given SenesTech an industry rank of 156 out of 265 based on the ratings given to its competitors.
A number of research analysts have weighed in on SNES shares. Roth Capital dropped their price objective on shares of SenesTech from $3.75 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, December 28th. Craig Hallum set a $3.00 price objective on shares of SenesTech and gave the company a “buy” rating in a research note on Wednesday, November 22nd. Finally, Zacks Investment Research raised shares of SenesTech from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th.
SenesTech (SNES) traded up $0.09 during trading on Monday, hitting $0.83. 1,609,800 shares of the company’s stock were exchanged, compared to its average volume of 359,067. SenesTech has a 12-month low of $0.56 and a 12-month high of $10.69. The company has a market capitalization of $13.09 and a price-to-earnings ratio of -0.62. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.94 and a quick ratio of 2.67.
SenesTech (NASDAQ:SNES) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. SenesTech had a negative net margin of 14,473.40% and a negative return on equity of 190.41%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.25 million. sell-side analysts forecast that SenesTech will post -1.16 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. TCI Wealth Advisors Inc. purchased a new stake in shares of SenesTech in the third quarter valued at about $748,000. Prudential PLC raised its holdings in shares of SenesTech by 49.3% in the second quarter. Prudential PLC now owns 447,971 shares of the company’s stock valued at $2,661,000 after purchasing an additional 147,971 shares during the last quarter. Gilder Gagnon Howe & Co. LLC raised its holdings in shares of SenesTech by 3.0% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 1,078,499 shares of the company’s stock valued at $1,995,000 after purchasing an additional 31,330 shares during the last quarter. Finally, Skylands Capital LLC raised its holdings in shares of SenesTech by 139.8% in the third quarter. Skylands Capital LLC now owns 87,483 shares of the company’s stock valued at $162,000 after purchasing an additional 51,000 shares during the last quarter. Institutional investors own 14.44% of the company’s stock.
WARNING: “Zacks: SenesTech Inc (SNES) Receives Average Recommendation of “Strong Buy” from Brokerages” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/15/zacks-senestech-inc-snes-receives-average-recommendation-of-strong-buy-from-brokerages.html.
SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.
Get a free copy of the Zacks research report on SenesTech (SNES)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.